Introduction
============

Programmed death-1 (PD-1) inhibitors, including pembrolizumab and nivolumab, can activate T cells to kill tumor cells by blocking the binding of the PD-1 receptor and programmed death ligand 1 and 2 (PD-L1 and PD-L2) ([@b1-mco-0-0-2042]). It is important to note that the dramatic efficacies of PD-1 inhibitors commonly accompanied by fatal side effects such as cardiotoxicity, pneumonitis and neurological toxicities ([@b2-mco-0-0-2042]). Guillain-Barre syndrome (GBS) is a rare but fatal autoimmune-mediated peripheral neuropathy characterized by muscular weakness in the extremities and peripheral paresthesia. The pathogenesis of GBS is the autoimmune response caused by molecular mimicry between microbial and nerve antigens ([@b3-mco-0-0-2042]). The present study reports on the case of a patient with advanced renal cell carcinoma who received pembrolizumab combined with sunitinib and presented with GBS. To date, no similar case has been reported. We reviewed some literatures to analyze the underlying mechanism of this rare disease and we aim to highlight that early recognition and suitable management is crucial to improve patient outcomes.

Case report
===========

A 55-year-old male presented with a right renal mass on CT scan. He was diagnosed with renal clear cell carcinoma with sarcomatoid differentiation after robot-assisted laparoscopic resection of the local mass ([Fig. 1](#f1-mco-0-0-2042){ref-type="fig"}). Adjuvant targeted therapy with sunitinib (50 mg/day; 2 weeks on, 1 week off) was performed for six cycles. On March 21st 2018, a CT scan revealed local recurrence, and spleen and abdominal cavity metastasis ([Fig. 2](#f2-mco-0-0-2042){ref-type="fig"}). As a result of this, the patient was started on pembrolizumab (2 mg/kg once every 3 weeks) combined with sunitinib (37.5 mg/day; 2 weeks on, 1 week off) on March 27th 2018. After 4 months, the patient developed limb weakness and numbness of the extremities. Neurological examination showed paresthesia of the four extremities, absence of tendon reflex of the limbs, and a mild decrease in muscle strength of the limbs with a grade of 4/5, but no pathological reflex was observed. This patient had no history of GBS, and laboratory examination results showed no evidence of infection. Procalcitonin, c-reactive protein, influenza virus antibody, cytomegalovirus antibody, rubella virus antibody, herpes simplex virus antibody, Epstein-Barr virus antibody, detection of mycoplasma and chlamydia DNA, and hepatitis virus tests were all negative. Rheumatic immune disease was also ruled out. Magnetic resonance imaging of the brain and spinal cord was normal. Cerebrospinal fluid (CSF) analysis showed albuminocytologic dissociation (protein, 583.30 mg/l; cell count, 8,000/µl), and Pandy\'s test was positive. Electroneuromyography revealed acute motor and sensory axonal neuropathy ([Fig. 3](#f3-mco-0-0-2042){ref-type="fig"}). Based on these results, the patient was diagnosed with GBS, which can be induced by pembrolizumab. Pembrolizumab was permanently discontinued due to this severe immune-related adverse event (irAE). The symptoms were gradually aggravated after oral treatment with dexamethasone (10 mg/day). The patient was then switched to intravenous immunoglobulin (IVIG; 0.4 g/kg for 5 days) along with prednisone (1 mg/kg per day). The patient\'s symptoms improved during 1 week of treatment. After 1 month, although he experienced difficulty with fine movements, he was able to walk and stand normally, and the doctors began to taper off the prednisone dosage. CT scan reexamination showed that the masses in the right kidney and abdominal cavity had disappeared, and the enhancement degree of spleen metastases was reduced ([Fig. 4](#f4-mco-0-0-2042){ref-type="fig"}). No recurrence was observed during the 10 months of follow-up.

Discussion
==========

Pembrolizumab is a potent and highly selective fully human IgG4 PD-1 immune-checkpoint inhibitor. Studies have confirmed its efficacy in several types of advanced cancer, such as melanoma, non-small cell lung cancer, head and neck carcinoma and renal cancer ([@b3-mco-0-0-2042]). Immunotherapy can cause a series of irAEs, including skin reactions, colitis, hepatitis, endocrinopathies, pneumonitis and, rarely, neurological toxicity ([@b7-mco-0-0-2042],[@b8-mco-0-0-2042]).

GBS is an autoimmune-mediated disease in which most patients have prodromal infection. Common infectious pathogens include cytomegalovirus, Epstein-Barr virus, influenza virus, human immunodeficiency virus, mycoplasma, *Haemophilus* and *Campylobacter jejuni* ([@b1-mco-0-0-2042]). It is now believed that the primary pathogenesis is the autoimmune response caused by molecular mimicry between microbial and nerve antigens. Both cellular and humoral immunity are abnormally activated. T cells invade the peripheral nerves, and peripheral demyelination is mediated by macrophages. Immunoglobulin and complement deposits appear on the myelin sheath and Schwann cells ([@b9-mco-0-0-2042]). Regulatory T cells (Treg cells) can downregulate the immune response, maintain autoimmunological tolerance, and prevent autoimmune diseases ([@b10-mco-0-0-2042]). The binding of PD-1 and its ligands PD-L1/PD-L2 causes CD25^+^Foxp3^+^ Treg cells to suppress anti-tumor immunity ([@b11-mco-0-0-2042]), and an increase in the number of CD25^+^Foxp3^+^ Treg cells has been reported in many malignant tumors ([@b12-mco-0-0-2042]), which is often associated with poor prognosis ([@b16-mco-0-0-2042]). The effect of PD-1 inhibitors is not limited to tumor-specific T cells, and blocking PD-1/PD-L1 and PD-L2 signals not only promotes anti-tumor immunity, but it also inhibits the generation of Treg cells in normal tissues, causing autoimmune adverse events ([@b11-mco-0-0-2042]). The patient in the present study had no symptoms of preexisting infection, and influenza virus, Epstein-Barr virus, human immunodeficiency virus, mycoplasma, hepatitis virus and cytomegalovirus infection were excluded by laboratory tests. It has been suggested that pembrolizumab may cause immune hyperfunction by increasing T cell activity, promoting T cell proliferation and inhibiting Treg cell function, thus disrupting immune homeostasis and inducing GBS.

Sunitinib is a multi-target tyrosine kinase receptor inhibitor targeting vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor-α receptor (PDGFR-α), PDGFR-β, stem cell receptor and colony-stimulating factor 1 receptor, which was approved by the US Food and Drug Administration for the first-line treatment of metastatic renal cell carcinoma, and postoperative adjuvant treatment of renal cell carcinoma with a high risk of recurrence ([@b17-mco-0-0-2042],[@b18-mco-0-0-2042]). In the KEYNOTE-426 study, pembrolizumab in combination with acitinib for advanced renal cell carcinoma significantly improved median progression-free survival (15.1 months vs. 11.1 months) over sunitinib alone ([@b6-mco-0-0-2042]), suggesting that pembrolizumab combined with a multi-target tyrosine kinase receptor inhibitor may be a promising treatment option. The most common side effects of sunitinib include fatigue, anorexia, hypertension, myelosuppression, diarrhea, mucositis, rashes and hand-foot syndrome ([@b19-mco-0-0-2042]). GBS developed in the patient in the present study, who had favorable responses to sunitinib in combination with pembrolizumab. Currently, two cases of GBS induced by sunitinib have been reported ([@b20-mco-0-0-2042],[@b21-mco-0-0-2042]), to the best of our knowledge, and the mechanism may be related to the sunitinib-mediated inhibition of VEGFRs causing a corresponding increase in VEGF levels, which increases the numbers of B lymphocytes and immature myeloid cells ([@b22-mco-0-0-2042]). Elevated VEGF levels may also disrupt the blood-nerve barrier by altering microvascular permeability ([@b22-mco-0-0-2042]). Considering that both T cells and B cells are important in the pathogenesis of GBS, it is speculated that combination therapy may have a synergistic pathogenicity. However, further studies are warranted to confirm this hypothesis.

Management of irAEs must never be disregarded. In the PubMed database, eight cases of nivolumab and four cases of pembrolizumab causing GBS have been reported ([@b23-mco-0-0-2042]) ([Table I](#tI-mco-0-0-2042){ref-type="table"}). Many of these cases were treated with nivolumab or pembrolizumab monotherapy (10/13); two patients were treated with ipilimumab and nivolumab in combination, and one was treated with pembrolizumab followed by sequential dabrafenib and trametinib. Most cases were male (9/12), and the neurological symptoms were mostly sensory and movement disorders, and reduced or absent deep tendon reflexes and only one patient had a precursor infection. CSF tests showed that a high proportion of patients had albuminocytologic dissociation (9/12), and the etiological examinations were all negative. Most patients recovered with corticosteroids, IVIG and plasmapheresis, but two died of respiratory failure. The present patient did not improve with corticosteroids alone, but IVIG was effective, suggesting that IVIG may be suitable for checkpoint inhibitor-induced peripheral neuropathy, although corticosteroids are recommended for the management of irAEs. To the best of our knowledge, this is the first case of GBS during treatment with pembrolizumab in combination with sunitinib in advanced renal cell carcinoma, highlighting the importance of correctly identifying immune-related neurotoxicity and accumulating experience in the management of GBS induced by pembrolizumab and sunitinib.
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![Pathological findings. (A) Pathological analysis of the resected tumor specimen revealing clear cellular renal cell carcinoma (Fuhrman nuclear grade 2) with (B) sarcomatoid differentiation (stain, hematoxylin and eosin). Magnification, x100. Arrows indicate clear cellular renal cell carcinoma (Fuhrman nuclear grade 2) and sarcomatoid differentiation.](mco-13-01-0038-g00){#f1-mco-0-0-2042}

![CT scanning before combination therapy in March 2018. (A) Spleen metastasis: The arrow indicates the spleen mass. (B) Local recurrence: The arrow indicates right renal mass. (C) Abdominal cavity metastasis: The arrow indicates abdominal cavity mass.](mco-13-01-0038-g01){#f2-mco-0-0-2042}

![Electrophysiological examinations of motor nerves (scanning speed: 5 ms/D, sensitivity: 10 mV/D). (A) Amplitude of motor waves of right ulnar nerve decreased (wrist: 5.9 mV, above elbow: 4.8 mV). (B) Amplitude of motor waves of right tibial nerve decreased (ankle: 5.4 mV, knee: 4.2 mV). (C) Amplitude of motor waves of left peroneal nerve decreased (Ankle: 1.4 mV, Below knee: 1.2 mV). (D) Amplitude of motor waves of Right peroneal nerve is normal (Ankle: 2.2 mV, Below knee: 2.0 mV). Normal range of the amplitude of motor nerves are as follow: Ulnar nerve: ≥5.0 mV, tibial nerve: ≥4.8 mV and peroneal nerve: ≥2.0 mV. Electrophysiological examinations of sensory waves (Scanning speed: 3 ms/D, Sensitivity: 10 uV/D): The Sensory waves of (E) left superficial peroneal nerve, (F) right median nerve, (G) right superficial peroneal nerve and (H) right ulnar nerve (H) were not induced. Normal range of distal sensory nerve action potential: Median nerve: ≥13.86 µV; ulnar nerve: ≥10.77 µV; and sural nerve: ≥7.71 µV.](mco-13-01-0038-g02){#f3-mco-0-0-2042}

![CT scanning after combination therapy in August 2018. (A) Arrow indicates the enhancement degree of spleen metastases was reduced. (B) Arrow indicates the right renal mass has disappeared. (C) Arrow indicates the abdominal cavity metastasis has disappeared.](mco-13-01-0038-g03){#f4-mco-0-0-2042}

###### 

Literature regarding GBS induced by PD-1 inhibitors.

  Study                           Disease type     Checkpoint inhibitors                     GBS treatment                                    Outcome   CSF                              (Refs.)
  ------------------------------- ---------------- ----------------------------------------- ------------------------------------------------ --------- -------------------------------- -----------------------
  Fukumoto *et al*, 2018          NSCLC            Nivolumab                                 IVIG, steroids                                   Alive     Albuminocytologic dissociation   ([@b23-mco-0-0-2042])
  Gu *et al*, 2017                Melanoma         Nivolumab+ ipilimumab                     IVIG, steroids, plasma exchange, mycophenolate   Alive     Albuminocytologic dissociation   ([@b24-mco-0-0-2042])
  Jacob *et al*, 2016             NSCLC            Nivolumab                                 IVIG, plasma exchange                            Dead      Albuminocytologic dissociation   ([@b25-mco-0-0-2042])
  Kyriazoglou *et al*, 2019       Bladder cancer   Nivolumab                                 IVIG, steroids                                   Alive     Albuminocytologic dissociation   ([@b26-mco-0-0-2042])
  Nukui *et al*, 2018             Nasal cancer     Nivolumab                                 IVIG, steroids                                   Alive     Albuminocytologic dissociation   ([@b27-mco-0-0-2042])
  Schneiderbauer *et al*, 2017    Melanoma         Nivolumab                                 IVIG, steroids                                   Alive     Albuminocytologic dissociation   ([@b28-mco-0-0-2042])
  Supakornnumporn *et al*, 2017   Melanoma         Nivolumab+ ipilimumab                     IVIG, steroids                                   Alive     Albuminocytologic dissociation   ([@b29-mco-0-0-2042])
  Thapa *et al*, 2018             NSCLC            Nivolumab                                 IVIG, steroids                                   Alive     Normal                           ([@b30-mco-0-0-2042])
  Manam *et al*, 2018             NSCLC            Pembrolizumab                             IVIG, steroids, plasma exchange                  Alive     Albuminocytologic dissociation   ([@b32-mco-0-0-2042])
  Manam *et al*, 2018             Melanoma         Pembrolizumab-dabrafenib and trametinib   IVIG, steroids, plasma exchange                  Dead      Albuminocytologic dissociation   ([@b32-mco-0-0-2042])
  de Maleissye *et al*, 2016      Melanoma         Pembrolizumab                             IVIG, steroids                                   Alive     Albuminocytologic dissociation   ([@b31-mco-0-0-2042])
  Ong *et al*, 2018               NSCLC            Pembrolizumab                             IVIG, steroids                                   Alive     Unknown                          ([@b33-mco-0-0-2042])

PD-1, programmed death-1; GBS, Guillain-Barre syndrome; CSF, cerebrospinal fluid; NSCLC, non-small cell lung cancer; IVIG, intravenous immunoglobulin.
